Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Theoretical and Natural Science
Vol. 35, 26 April 2024
Open
Access | Article
Immunotherapies against HER2 positive breast cancer: focusing on monoclonal antibodies and therapeutic vaccines
* Author to whom correspondence should be addressed.
Abstract
HER2 positive breast cancer is prevalent in females, accounting for 31% female cancer worldwide. The pathology is due to the fact that overexpressed HER2 protein dimerize will others to cause constitutively signalling cascades inside the cells. Eventually, tumour develops due to uncontrolled proliferation. Immunotherapies have been researched significantly in treating this type of cancer, and this article focuses on the monoclonal antibodies and the therapeutic vaccines. Monoclonal antibodies, especially trastuzumab, significantly benefit in clinical outcomes. However, resistance developed against trastuzumab, and this urged the development of other novels mAb and antibody drug conjugates. On the other hand, even though none of the therapeutic vaccines have been approved, they are actively researched in clinical trials. With immunogenic peptides and efficient platforms are chosen, the therapeutic vaccine is expected to activate immune cells, resulting in elimination of tumour cells. Both approaches have drawbacks including drug resistance and the suppressive tumour microenvironment. Therefore, combined immunotherapies may be considered as potent treatment in the future.
Keywords
HER2 positive breast cancer, monoclonal antibodies, therapeutic vaccines
References
1. Siegel RL Miller KD Wagle NS et al 2023 Cancer statistics CA Cancer J Clin 73 17-48
2. Oh DY. Bang YJ. 2020 HER2-targeted therapies — a role beyond breast cancer Nat Rev Clin Oncol 17 33–48
3. Swain SM Shastry M Hamilton E. 2023 Targeting HER2-positive breast cancer: advances and future directions Nat Rev Drug Discov 22 101-126
4. Robert M Frenel JS Bourbouloux E et al 2020 Pertuzumab for the treatment of breast cancer Expert Rev Anticancer Ther 20 85-95
5. Rugo HS et al. 2021 Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial. JAMA Oncol. 7 573-584.
6. Davodabadi F Sarhadi M Arabpour J et al 2022 Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches J Control Release 349 844-875
7. Nordin ML Azemi AK Nordin AH et al 2023 Peptide-Based Vaccine against Breast Cancer: Recent Advances and Prospects Pharmaceuticals (Basel) 16 923
8. Zhang Y Lin S Wang XY Zhu G. 2019 Nanovaccines for cancer immunotherapy Wiley Interdiscip Rev Nanomed Nanobiotechnol 11 1559
9. Maadi H.; Soheilifar M.H.; Choi W.-S.; Moshtaghian A.; Wang Z. 2021 Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma Cancers 13 35-40
10. Revathidevi S Munirajan AK. 2019 Akt in cancer: Mediator and more. Semin Cancer Biol 59 80-91
11. Miricescu D Totan A Stanescu-Spinu II Badoiu SC Stefani C Greabu M. 2020 PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects Int J Mol Sci. 22 173
12. Musolino A et al 2022 Role of Fcγ receptors in HER2-targeted breast cancer therapy. Journal for ImmunoTherapy of Cancer 10 3171
13. Derakhshani A Rezaei Z Safarpour H et al2020 Overcoming trastuzumab resistance in HER2-positive breast cancer using combination therapy J Cell Physiol. 235 3142-56
14. Costa R.L.B. Czerniecki B.J. 2020 Clinical development of immunotherapies for HER2+ breast cancer: a review of HER2-directed monoclonal antibodies and beyond npj Breast Cancer 6 10
15. de Melo Gagliato D Jardim DL Marchesi MS Hortobagyi GN. 2016 Mechanisms of resistance and sensitivity to anti-HER2 therapies in HER2+ breast cancer. Oncotarget 7 64431-46
16. Zhu SY Yu KD. 2022 Breast Cancer Vaccines: Disappointing or Promising? Front Immunol 13 82-6
17. Neek M Kim TI Wang SW. 2019 Protein-based nanoparticles in cancer vaccine development. Nanomedicine 15 164-174
18. Morse MA Gwin WR 3rd Mitchell DA. 2021 Vaccine Therapies for Cancer: Then and Now Target Oncol 16 121-152
19. Disis ML Cecil DL. 2022 Breast cancer vaccines for treatment and prevention Breast Cancer Res Treat 191 481-9
20. Hunter FW Barker HR Lipert B Rothé F Gebhart G Piccart-Gebhart MJ Sotiriou C Jamieson SMF. 2020 Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer Br J Cancer. 122 603-612
21. Barzaman K Moradi-Kalbolandi S Hosseinzadeh A Kazemi MH Khorramdelazad H Safari E Farahmand L. 2021 Breast cancer immunotherapy: Current and novel approaches Int Immunopharmacol 98 107886
22. Leung KL Verma D Azam YJ Bakker E. 2020 The use of multi-omics data and approaches in breast cancer immunotherapy: a review Future Oncol 16 2101-19
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the 2nd International Conference on Modern Medicine and Global Health
- ISBN (Print)
- 978-1-83558-395-1
- ISBN (Online)
- 978-1-83558-396-8
- Published Date
- 26 April 2024
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/35/20240905
- Copyright
- 26 April 2024
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited